NEUROIMAGING CORE

在过去的周期中，神经成像核心经历了相当大的生产力。这种增长在很大程度上归功于一个专注的多学科教师创造的智囊团氛围。一个不断增长的神经成像工具库，专门为新的ADCC项目创建，在MIDAS软件包中开发和分发。核心支持27个资助项目和科学合作，所有常规临床和研究ADCC神经影像学检查，以及多机构神经影像学培训。在当前的周期中，Core已经为图像采集，图像配准，解剖验证和图像分析项目做出了贡献，这些项目展示了它们在模式内和跨模式的价值，现在扩展到转基因小鼠成像。这一循环导致首次PET和MR成像观察正常人内侧颞叶脑的变化，预测未来MCI和AD。我们开发了一种区域边界移位算法，该算法显示了MCI之前萎缩年份的增加率。报道了海马体的首次交叉模态（MR-PET）研究。通过开发图像分析软件并使应用程序用户友好，Core资源直接负责这些成就。Core还进行了死后磁共振成像和组织解剖学研究，以验证海马体和内嗅皮层的体内测量结果。我们提出了5个具体目标，包括：硬件和软件支持新的和现有的项目，包括多中心人类成像合作和新的研究人员；活体人体杏仁核和耻骨下成像的病理学新验证标准化小鼠纵向成像方案与死后淀粉样蛋白分布验证；MR和PET成像的统一采集和质量控制

The Neuroimaging Core has experienced considerable productivity during the past cycle. This growth is in large measure attributable to the think tank atmosphere created by a dedicated multidisciplinary faculty. A growing arsenal of neuroimaging tools, specifically created for new ADCC projects, was developed and distributed in the MIDAS software package. The Core supports 27 funded projects and scientific collaborations, all the routine clinical and research ADCC neuroimaging examinations, and multi-institutional neuroimaging training. In the current cycle the Core has contributed to image acquisition, image registration, anatomical validation, and image analysis projects that demonstrated their value within and across modalities and are now extended to transgenic mouse imaging. This cycle has led to the first PET and MR imaging observations of medial temporal lobe brain changes in normal individuals that predict future MCI and AD. We developed a regional boundary shift algorithm that demonstrates increased rates of atrophy years prior to MCI. The first cross-modality (MR-PET) studies of the hippocampus were reported. Core resources were directly responsible for these accomplishments by developing image analysis software and making the applications user friendly. The Core has also conducted post mortem MR and histological anatomical studies to validate in vivo measurements of the hippocampus and entorhinal cortex. We propose 5 specific aims that include: hardware and software support for new and existing projects including multi-center human imaging collaborations and new investigators; new pathological validations for in vivo human amygdala and subiculum imaging; standardized longitudinal mouse imaging protocols with post mortem amyloid distribution validation; uniform acquisition and quality control for MR and PET imaging data; the development of new imaging and biomarker protocols to improve AD diagnostic specificity; and for testing hypotheses related to glucose transport and perfusion in normal aging and diabetes.